Delivery Order 36F79724D0185-36C24926N0676
Award Date 8/24/26
Potential Completion Date 9/30/26
Potential Value $69K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on April 28, 2026, under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule for Galafold 123 mg. Performance is at Philadelphia, PA, with an ultimate completion date of May 4, 2026. The parent vehicle is the GSA Federal Supply Schedule contract (FSS-61-IB), a multiple-award schedule enabling VA networks nationwide to procure pharmaceutical products including enzyme replacement...
- Veterans Integrated Service Network 9 issued a delivery order to Amicus Therapeutics US, LLC on May 27, 2026, for Galafold (migalastat) 123 mg capsules with a ceiling value of $68,518.83. The order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), a multiple-award GSA Schedule contract valued at $13,024,630 and effective through August 31, 2029. Place of performance is Murfreesboro, TN. The order is firm fixed price with an ultimate completion date of August...
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on July 1, 2026, for Galafold (migalastat) 123 mg under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Place of performance is Philadelphia, PA 19104. The order is due July 7, 2026. The requirement is for Galafold 123 mg capsules, an FDA-approved enzyme replacement therapy indicated for treatment of Fabry disease in veterans. Pricing is firm fixed price with no...
- Veterans Integrated Service Network 5 issued a $22,839.61 delivery order to Amicus Therapeutics US, LLC on April 7, 2026, for Galafold 123 mg under the GSA Schedule Pharmaceuticals and Drugs (FSS-61-IB). The parent contract is a multiple-award Federal Supply Schedule vehicle (36F79724D0185) valued at $13.024 million, effective through August 31, 2029, enabling VA medical centers nationwide to procure specialized pharmaceutical products. Place of performance is Philadelphia, PA. The order is firm...
- Veterans Integrated Service Network 7 issued a $228,396.10 delivery order to Amicus Therapeutics US, LLC on February 23, 2026, for Galafold medication under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The parent Federal Supply Schedule contract, effective through August 31, 2029, enables VISNs across the Department of Veterans Affairs to procure Galafold (migalastat) 123 mg, an FDA-approved enzyme replacement therapy for Fabry disease treatment. Place of performance is...
- The Department of Veterans Affairs, Veterans Integrated Service Network 9 (VISN 9), awarded a delivery order valued at $68.5K to Amicus Therapeutics US, LLC for emergency pharmacy supply of Galafold (migalastat 123 mg), an FDA-approved enzyme replacement therapy for the treatment of Fabry disease. This firm fixed-price delivery order, with an ultimate completion date of June 4, 2026, will be performed in Philadelphia, PA. The award carries no set-aside designation and represents a continuation...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order valued at $21,891.21 to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg on November 20, 2025, with an ultimate completion date of November 25, 2025. This firm fixed-price delivery order, with no set-aside designation, represents a task order placed under Amicus Therapeutics' existing Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The...
- This is a $21,891.21 firm fixed-price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the delivery of GALAFOLD 123 MG, an enzyme replacement therapy used to treat Fabry disease, to the VA's Veterans Integrated Service Network 5 (VISN 5) in Philadelphia, Pennsylvania. The contract was awarded on September 24, 2025 and has a completion date of September 29, 2025. The...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a delivery order against the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule to Amicus Therapeutics US, LLC for $20,124.91. The firm fixed price order is for GALAFOLD 123 MG and has a completion date of May 19, 2023. Amicus Therapeutics US, LLC is a subsidiary of Amicus Therapeutics, Inc., which is currently operating as a development stage company. The order was awarded on May...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a $20,124.91 delivery order against the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule to Amicus Therapeutics US, LLC for GALAFOLD 123 MG. The firm fixed price order has a completion date of January 9, 2023 and was awarded on January 5, 2023. Amicus Therapeutics US, LLC is a subsidiary of Amicus Therapeutics, Inc., which is currently operating as a development stage company....